Monitor the outcome of the proxy vote and whether Altai gains board seats. Upcoming FDA decisions on CT/NG and Colli-Pee in 2026 will be critical catalysts. Insider buying and the repurchase program suggest management confidence, but revenue growth has not yet materialized.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 18 $2.90entry
- T+1 · 8mo ago +0.34%α +0.61% · $2.91
- T+5 · 8mo ago +8.28%α +8.99% · $3.14
- T+20 · 7mo ago +10.69%α +4.64% · $3.21
- T+60 · 5mo ago +44.48%α +32.96% · $4.19
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
OraSure Technologies filed a definitive proxy statement (DEFA14A) in response to an activist campaign by Altai Capital, which is pushing for board representation to force a sale of the company. OraSure's management defends its transformation strategy, highlighting upcoming product launches, cost reductions, and a $40 million share buyback, while accusing Altai's founder of seeking personal control rather than shareholder value.
Key Facts
- OraSure is facing a proxy contest from activist investor Altai Capital, which seeks board representation to push for a sale.
- The company has rejected Altai's demands, stating it is at a strategic inflection point with key product launches in 2026.
- OraSure highlights operational progress: 40% workforce reduction, 37% SG&A cost cut since 2022, and ~260 bps gross margin expansion.
- The company submitted FDA applications for two high-impact STI tests targeting a $2B market.
- OraSure announced a $40 million share repurchase program and leadership stock purchases to signal confidence.
- Altai rejected settlement offers, including the appointment of its nominee John Bertrand and a board declassification proposal.
Financial Impact
$40 million share repurchase program announced; no specific revenue or earnings figures provided
Risk Factors
- Proxy contest could lead to board instability or strategic disruption.
- Failure to achieve FDA clearance for key products in 2026 would undermine growth strategy.
- Revenue growth remains forward-looking with no current financial improvement confirmed.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001193125-26-111262 |
| Document: 0001193125-26-111262-index-headers.html | 0001193125-26-111262 |
| Document: 0001193125-26-111262-index.html | 0001193125-26-111262 |
| Document: 0001193125-26-111262.txt | 0001193125-26-111262 |
Track record
20 reports on OSUR
6 of 6 bullish or bearish reports moved the stock their way by T+1. Best: +39.73% at T+60 after the Mar 13, 2026 report. 6 of 6 went positive at some point.
Filters
- Nov 12, 20264d ago 10-Q/A Neutral 2/10 Entry $3.62 to $3.62 Now $3.60 −0.55% · 0.00% +0.36% vs SPY
- Nov 9, 20267d ago Press Release Neutral 4/10 Entry $3.33 to $3.56 Now $3.60 +8.11% ▲ +6.91% +5.59% vs SPY
- Nov 9, 20267d ago SC 13G/A Neutral 3/10 Entry $3.53 to $3.33 Now $3.60 +1.98% ▼ −5.67% −5.30% vs SPY
- Nov 2, 202614d ago Press Release Neutral 2/10 Entry $3.46 to $3.53 Now $3.60 +4.20% ▲ +2.17% +1.87% vs SPY
- Oct 30, 202617d ago SC 13G/A Neutral 3/10 Entry $3.94 to $3.46 Now $3.60 −8.63% ▼ −12.31% −11.83% vs SPY
- Sep 17, 20268w ago SC 13D Bullish 6/10 Entry $3.56 to $3.69 Now $3.60 +1.12% ▲ +3.65% +2.10% vs SPY
- Jul 23, 202616w ago Court Ruling Neutral 3/10 Entry $3.97 to $3.96 Now $3.60 −9.32% ▼ −0.25% −0.27% vs SPY
- Jun 12, 202622w ago Institutional Cluster Mixed 4/10 Entry $4.18 to $4.17 Now $3.60 −13.88% ▼ −0.24% −2.00% vs SPY
- Jun 3, 202623w ago 8-K Neutral 3/10 Entry $4.17 to $4.04 Now $3.60 −13.67% ▼ −3.12% −0.52% vs SPY
- May 6, 202627w ago 8-K Bearish 6/10 Entry $3.13 to $3.06 Now $3.60 −15.02% ▲ +2.24% +3.07% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers